Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
cache
Home
cache
Next Post
Previous Post
cache
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
cache
Read More
Neil Desai, PhD
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
cache
A phase 2 trial with ABI-009 (
nab
-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)
UPDATE — Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
Read More
Andrew Kwon, PhD
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.